By Daniel Akselrod · Licensed Attorney · July 2026

Intake Forms for Compounding Pharmacies: Allergy Profiling, Medication History, and Custom Formulation Documentation

A compounding pharmacy does not simply count pills and slap a label on a stock bottle. Every preparation leaving the compounding lab is a custom-manufactured medication, built from raw ingredients for a specific patient with specific clinical needs. The intake process at a compounding pharmacy must therefore capture an entirely different depth and breadth of information than what a standard retail pharmacy collects. A chain pharmacy intake asks for a name, a date of birth, an insurance card, and a single allergy checkbox. A compounding pharmacy intake must map the full terrain of a patient's sensitivities, medication failures, formulation preferences, prescriber relationships, and clinical history before a single gram of active pharmaceutical ingredient touches a mortar and pestle.

The consequences of incomplete intake in compounding are not merely administrative. A compounded preparation made with a base that contains a preservative the patient is allergic to can trigger a systemic reaction. A hormone replacement cream compounded at the wrong concentration because the prescriber's protocol was not fully documented can produce dangerously supraphysiologic hormone levels. A pediatric suspension flavored with a dye the child cannot tolerate will be spit out, wasted, and billed again. Every one of these failures traces back to an intake form that did not ask the right questions. This article examines what a compounding pharmacy intake form must capture and why each section is clinically and legally necessary.

Allergy profiling for compounding: far beyond the standard drug allergy checkbox

Standard pharmacy intake forms ask whether the patient has drug allergies. Compounding pharmacy intake must go several layers deeper because the pharmacist is selecting every ingredient in the preparation, not dispensing a pre-manufactured product whose composition is fixed. When a retail pharmacist dispenses a manufactured tablet, the excipient profile is what it is. When a compounding pharmacist builds a preparation from scratch, every excipient is a choice, and every choice can be guided by allergy information that the intake form either captured or failed to capture.

Dye sensitivities represent the first layer that standard intake forms miss entirely. FD&C Yellow No. 5, known as tartrazine, appears in thousands of commercial oral medications and is a known trigger for urticaria, angioedema, and bronchospasm in sensitive individuals, particularly those with aspirin sensitivity. FD&C Red No. 40, Blue No. 1, and Yellow No. 6 each carry their own sensitivity profiles. Patients referred to compounding pharmacies have often been through years of unexplained reactions to commercial medications before anyone considers that the dye, not the active ingredient, is the problem. A compounding intake form that asks specifically about dye reactions captures the information that finally resolves these patients' histories of medication intolerance.

Preservative allergies constitute the second layer. Parabens, specifically methylparaben and propylparaben, are among the most common preservatives in pharmaceutical preparations and are also among the most common causes of contact dermatitis and hypersensitivity reactions. Benzalkonium chloride, used extensively in ophthalmic and nasal preparations, is cytotoxic to corneal epithelial cells in sensitive patients and can cause paradoxical worsening of the conditions the preserved product is meant to treat. Thimerosal, though largely removed from vaccines, still appears in some multi-dose vial preparations. Sulfite preservatives, including sodium metabisulfite and sodium sulfite, can trigger bronchospasm in asthmatic patients. A compounding pharmacy that does not document preservative sensitivities at intake will inevitably compound a preparation that contains the very preservative the patient was sent to compounding to avoid.

Excipient intolerances form the third and often most clinically significant layer. Lactose appears as a filler in a remarkable number of commercial tablets and capsules. Patients with severe lactose intolerance, not the common mild gastrointestinal variety but the kind that produces significant symptoms from the milligram quantities found in pharmaceutical fillers, are frequently referred to compounding for lactose-free alternatives. Gluten, present as a starch derivative in certain tablet formulations, matters for patients with celiac disease whose chronic gastrointestinal symptoms may be partly attributable to their daily medications. Casein, a milk protein, appears in some capsule formulations and can trigger reactions in patients with milk protein allergy as opposed to lactose intolerance. Soy lecithin, used as an emulsifier in certain preparations, is relevant for patients with soy allergy. Gelatin, derived from animal collagen and used in capsule shells, is relevant both for patients with gelatin allergy and for patients who avoid animal products for religious or ethical reasons and need vegetarian capsule alternatives. Each of these excipient sensitivities must be documented individually on the intake form because each one changes the compounding pharmacist's formulation decisions.

The intake form should also capture the severity and nature of each allergic or sensitivity reaction, not just a binary yes or no. A patient who experienced mild gastrointestinal discomfort from a lactose-containing tablet has a different clinical profile than a patient who experienced anaphylaxis from a casein-containing capsule. The compounding pharmacist needs to know whether a given sensitivity represents an inconvenience to be managed or a life-threatening reaction to be avoided absolutely. Reaction type, severity grade, date of occurrence, and whether the reaction was confirmed by allergy testing or is based on patient report should all be captured.

Medication history and commercial formulation failures

Patients arrive at compounding pharmacies because something about commercially available medications does not work for them. Understanding precisely what failed and why is the foundation of every compounding decision the pharmacist will make. A compounding intake form must therefore capture not just the current medication list but the medication history, including discontinued medications and the specific reasons they were stopped.

The current medication list itself must be more detailed than what standard pharmacy intake collects. For each medication, the form should capture the drug name, strength, dosage form, prescribing physician, dosing frequency, how long the patient has been taking it, and whether the patient considers it effective. This last point matters enormously in compounding because patients who report partial effectiveness from a commercial product at a given dose may benefit from a compounded formulation at the same dose in a different delivery vehicle that improves bioavailability, rather than a dose increase that the prescriber might otherwise order.

The commercial formulation failure history is unique to compounding intake and has no analog in standard pharmacy documentation. For each medication that was tried and discontinued, the intake form should capture the drug name, the dosage form that was tried, the manufacturer if known, the duration of the trial, the specific reason for discontinuation, and whether the failure was related to the active ingredient itself or to the formulation. A patient who cannot tolerate oral metformin due to gastrointestinal side effects but has no issue with the active ingredient is a candidate for a compounded transdermal metformin cream. A patient who tried three different commercial thyroid medications and experienced adverse effects from each needs a different compounding approach than a patient who simply cannot swallow the tablets. The distinction between active ingredient failure and formulation failure is clinically critical, and the intake form is the only place where it is systematically documented.

Over-the-counter medications, supplements, and herbal products must be captured with particular attention because they interact with compounded preparations just as they interact with commercial ones. A patient taking St. John's Wort, which induces CYP3A4 and CYP2C9, may metabolize a compounded hormone preparation more rapidly than expected. A patient on high-dose fish oil may have altered bleeding times that affect compounded pain management formulations containing aspirin or NSAIDs. A patient using topical essential oils on the same skin area where a transdermal compounded cream will be applied may experience altered absorption or local irritation. The intake form should ask specifically and separately about OTC medications, dietary supplements, herbal products, and topical products because patients do not spontaneously volunteer these and do not consider them medications.

Prescriber information and communication preferences

Compounding pharmacies maintain a different relationship with prescribers than retail pharmacies do. A retail pharmacist may call a prescriber once about a drug interaction or a formulary substitution. A compounding pharmacist engages in an ongoing clinical dialogue with the prescriber about formulation decisions, concentration adjustments, base selections, and therapeutic outcomes. The intake form must capture the information infrastructure that supports this dialogue.

For the primary prescriber who ordered the compounded medication, the form should capture the full name, credentials, practice name, office phone, direct clinical line if different from the main office number, fax number, preferred method of communication, and the prescriber's NPI number. The NPI is necessary for claims submission where compounded medications are covered, and the preferred communication method matters because some prescribers respond to fax within hours but take days to return phone calls, while others have secure messaging systems through their EHR that they check more frequently than either phone or fax.

The intake should also capture information about other prescribers managing the patient's care. Patients on compounded hormone replacement therapy, for example, often have an endocrinologist or functional medicine practitioner managing the hormones, a primary care physician managing everything else, and possibly a gynecologist or urologist involved in related care. When the compounding pharmacist identifies a potential interaction between the compounded hormone preparation and a medication prescribed by the PCP, the pharmacist needs to know who to call and how to reach them without routing through the patient as an intermediary.

Communication preferences for the patient must also be documented at intake. Can the pharmacy leave a voicemail message that mentions the medication name and that it is ready for pickup? Can the pharmacy send text messages about the order? Can the pharmacy discuss the prescription with a spouse, parent, caregiver, or authorized representative? These are HIPAA disclosure decisions, and in compounding they arise more frequently than in retail because compounded medications often have longer preparation times, may require multiple calls about formulation adjustments, and sometimes involve follow-up consultations about therapeutic response. Documenting these preferences at intake prevents your staff from making ad hoc HIPAA disclosure decisions at the counter or on the phone, which is how privacy violations happen.

Patient preferences: dosage form, flavor, and delivery vehicle

The entire point of compounding is customization, and the intake form is where the pharmacist learns what customization the patient actually needs. A prescription that says "progesterone 100mg capsules" tells the compounding pharmacist the active ingredient and the strength but says nothing about the patient's preferences for capsule size, whether the patient can swallow capsules at all, whether a different dosage form might improve adherence or bioavailability, or whether there are formulation preferences that would make the medication more tolerable.

Dosage form preference is the most fundamental customization question. Compounding pharmacies can produce oral capsules, oral suspensions, sublingual troches and rapid-dissolve tablets, topical creams and gels, transdermal preparations designed for systemic absorption, suppositories and rectal preparations, vaginal suppositories and creams, nasal sprays, ophthalmic solutions, and in some cases injectable preparations. Each dosage form has distinct bioavailability characteristics, onset times, duration of action profiles, and patient acceptance patterns. A patient who has been prescribed an oral medication but consistently misses doses because of dysphagia may achieve far better therapeutic outcomes with a transdermal cream applied once daily. A hospice patient who can no longer swallow may need a sublingual or rectal formulation of the same medication they have been taking orally for years. The intake form must ask about swallowing difficulties, physical dexterity limitations that affect application of topical products, cognitive factors that affect dosing complexity, and the patient's own preferences for how they take their medications.

Flavor preferences are critically important for pediatric compounding and are relevant for any oral liquid preparation. Children are notoriously difficult to medicate, and a compounded suspension that tastes terrible to a specific child will not be taken regardless of how clinically necessary it is. The intake form should ask about preferred flavors, known flavor aversions, and any flavor sensitivities. Some children will take bubblegum flavoring but refuse grape. Some reject anything with a sour or citrus profile. Some have sensory processing differences that make certain textures or flavor intensities intolerable. Capturing this information at intake prevents the waste and frustration of compounding a preparation that the patient refuses to take, and it prevents the pharmacy from having to recompound the same prescription in a different flavor at no additional charge because the first version was unacceptable.

For topical and transdermal preparations, the intake form should capture preferences regarding the base vehicle. Some patients prefer a vanishing cream that absorbs quickly and does not leave a residue. Others prefer a thicker ointment base for its emollient properties. Some need a gel for application to hairy areas where creams do not absorb well. The presence of fragrance sensitivities, prior skin reactions to specific bases or vehicles, and the application site all affect the pharmacist's base selection. A transdermal hormone cream applied to the inner wrist has different vehicle requirements than one applied to the inner thigh, and the intake form is where this information is captured before the prescription is compounded.

Hormone replacement therapy documentation: the clinical protocol record

Bioidentical hormone replacement therapy is one of the highest-volume and highest-margin services offered by compounding pharmacies, and it is also one of the most documentation-intensive. HRT patients require intake documentation that goes well beyond the standard medication history because hormone therapy is titrated over time based on laboratory results, symptom tracking, and clinical response. The intake form for an HRT patient is not just a snapshot of current medications. It is the first entry in an ongoing clinical record that the compounding pharmacist will reference and update at every refill.

The intake form should capture the patient's complete hormone-related laboratory results, including the most recent values for estradiol, progesterone, testosterone (total and free), DHEA-S, cortisol (morning or four-point salivary if available), thyroid panel (TSH, free T3, free T4), and sex hormone binding globulin. The date of each lab draw must be documented because hormone levels fluctuate and a lab result from six months ago may not reflect the patient's current status. The prescriber's target ranges should also be noted because different practitioners target different hormone levels, and the compounding pharmacist needs to understand the prescriber's therapeutic intent to assess whether a dose adjustment request makes clinical sense.

Symptom tracking at intake establishes the baseline against which therapeutic response will be measured. For menopausal and perimenopausal patients, the intake should document the frequency and severity of hot flashes, night sweats, sleep disturbance, mood changes, vaginal dryness, decreased libido, cognitive fog, joint pain, and weight changes. For male patients on testosterone replacement, the intake should document energy levels, libido, erectile function, mood, sleep quality, muscle mass changes, and body composition. A simple symptom severity scale, such as a zero to ten rating for each symptom, provides a quantitative baseline that allows both the prescriber and the pharmacist to assess whether the compounded therapy is producing the expected clinical improvement at each refill.

Prior hormone protocols must be documented in detail. Many HRT patients have been through multiple providers and multiple formulation changes before arriving at a compounding pharmacy. The intake should capture every prior hormone regimen the patient has tried, including the specific hormones, the doses, the dosage forms, the duration of each protocol, the laboratory results during each protocol if available, and the reason each protocol was changed or discontinued. A patient who experienced breast tenderness on oral estradiol at 2mg daily but not on transdermal estradiol at 0.1mg daily provides the compounding pharmacist with clinically actionable information about bioavailability and first-pass metabolism that directly informs the formulation of the compounded preparation.

The intake form should also capture information about the patient's menstrual history, surgical history relevant to hormones (hysterectomy, oophorectomy, orchiectomy), and family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate). This information does not change the compounding pharmacist's formulation per se, but it is essential context for clinical consultations with the prescriber and for identifying red flags that should prompt the pharmacist to verify the prescriber's clinical rationale before compounding a potentially inappropriate preparation.

Veterinary compounding: species, weight, and palatability

A significant and growing segment of compounding pharmacy revenue comes from veterinary prescriptions. Dogs, cats, horses, and exotic animals frequently need compounded medications because commercially available veterinary formulations do not exist for many drugs, because the available dosage forms are impractical for certain species, or because the animal cannot tolerate the commercially available formulation. Veterinary compounding introduces intake requirements that have no parallel in human pharmacy, and a compounding pharmacy that serves veterinary patients needs a dedicated section on its intake form or a separate veterinary intake form entirely.

Species identification is the most fundamental data point because drug metabolism, toxicity profiles, and dosage calculations vary dramatically across species. A dose of acetaminophen that is therapeutic in a dog is lethal in a cat. Ivermectin doses that are routine in most dog breeds cause fatal neurotoxicity in Collie-type breeds with the MDR1 gene mutation. NSAID selection in horses follows entirely different safety profiles than in small animals. The intake form must capture the species, breed, and any known breed-specific drug sensitivities because the compounding pharmacist must verify that the prescribed drug, dose, and formulation are appropriate for that specific animal.

Weight is critical for veterinary compounding in a way that it is optional for most human prescriptions. Veterinary doses are almost universally calculated on a per-kilogram basis, and the weight range across veterinary patients is enormous. A compounding pharmacist preparing a suspension for a 3-kilogram cat and a 45-kilogram dog needs to prepare vastly different concentrations to achieve practical dosing volumes, and the weight documented at intake is the starting point for these calculations. The intake should also capture when the weight was last measured because animals, especially those being treated for chronic conditions, may gain or lose significant weight between visits.

Palatability is the veterinary equivalent of the flavor preference question in pediatric compounding, but it is arguably more important because you cannot reason with a cat. Dogs will generally accept beef, chicken, liver, and peanut butter flavoring. Cats are notoriously finicky and may accept tuna or chicken flavoring but reject everything else. Horses will take apple and molasses. Exotic species have their own palatability profiles that the prescribing veterinarian or the pet owner can inform. The intake form should capture flavor preferences, known aversions, and the dosage form most practical for the animal. A cat owner who cannot pill a cat needs a transdermal gel or a flavored liquid. A horse owner who needs to treat a pastured horse that comes to the fence but does not stand for oral dosing needs a top-dress powder that mixes into feed. Capturing this at intake prevents the pharmacy from compounding a preparation that the animal's owner cannot successfully administer.

The intake should also document the prescribing veterinarian's information, the animal's diagnosis or condition being treated, any concurrent medications, and known drug allergies or adverse reactions in that specific animal. Veterinary patients cannot report their own symptoms or side effects, so the intake form must capture the owner's observations about the animal's response to prior medications.

State board of pharmacy compliance: 503A versus 503B documentation

Compounding pharmacies operate under one of two federal regulatory frameworks, and the intake documentation requirements differ between them. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications based on individual patient prescriptions. Section 503B governs outsourcing facilities that compound larger batches without patient-specific prescriptions, often for hospitals and clinics. Most independent compounding pharmacies operate under 503A, but some maintain dual registration, and the intake form must support the documentation requirements of whichever framework applies.

Under 503A, the compounding pharmacy must compound pursuant to a valid prescription for an identified individual patient. This means the intake form must clearly identify the patient, link to a specific prescription, and document that the compounded preparation is not essentially a copy of a commercially available product unless the prescriber has documented a clinical reason for the compounded version. The intake form is the first link in this documentation chain. A well-designed intake form that captures the patient's specific sensitivities, formulation failures with commercial products, and clinical reasons for needing a compounded preparation provides the documentation that justifies compounding under 503A if the pharmacy is ever audited by a state board or the FDA.

State boards of pharmacy impose their own requirements on top of the federal framework, and these vary significantly. Some states require specific informed consent disclosures for compounded medications, informing the patient that the preparation has not been FDA-approved and that quality controls differ from manufactured products. Some states require documentation of the source of the prescription and verification that the prescriber is licensed in the state. Some states require specific record-keeping about the compounding process itself, including the master formula, the compounding log, and the beyond-use dating calculation, all of which trace back to the patient-specific information captured at intake. The intake form should include or reference whatever state-specific consent and disclosure requirements apply in the pharmacy's jurisdiction.

Quality assurance and beyond-use dating documentation, while primarily production-side concerns, connect to intake through the patient's usage patterns. A compounded preparation assigned a 30-day beyond-use date is appropriate for a local patient who picks up monthly. That same preparation may be inappropriate for a patient who lives two hours away, picks up every 90 days, and stores the medication in a hot garage. The intake form should capture the patient's expected pickup frequency, storage conditions, and any factors that affect the stability timeline the pharmacist must consider when assigning beyond-use dates. The connection between intake and compounding quality is not immediately obvious, but it is real and it is auditable.

Insurance, payment, and patient financial expectations

Compounded medications occupy an unusual position in the pharmacy reimbursement landscape. Most commercial insurance plans and PBMs either do not cover compounded preparations at all or cover them only under specific conditions with prior authorization. Workers' compensation and auto insurance may cover compounded pain management or wound care preparations. Some patients pay entirely out of pocket. The intake form must set financial expectations clearly because a patient who assumes their insurance will cover a compounded hormone cream and discovers at pickup that the cost is two hundred dollars out of pocket is a patient who refuses the prescription, wastes the pharmacy's compounding time and materials, and does not come back.

The intake should capture the patient's insurance information in full, including the pharmacy benefit details, any secondary coverage, and whether the patient has been informed that compounded medications may not be covered. If the pharmacy offers its own payment plans, discount programs, or subscription pricing for recurring compounded prescriptions, the intake form is the place to introduce these options and capture the patient's preferences. Some compounding pharmacies offer monthly subscription pricing for HRT patients whose prescriptions are stable and predictable. Enrolling the patient in that program at intake, rather than at the third or fourth refill, improves retention and reduces the billing friction that causes patients to drift back to commercial alternatives.

The intake form should also capture the patient's preferred payment method, their authorization for recurring charges if applicable, and whether they want a cost estimate before the pharmacy begins compounding. This last point is particularly important for compounding because unlike retail pharmacy, where the patient's copay is usually known before dispensing, compounding costs can vary based on the ingredients, the quantity, and the complexity of the preparation. A patient who does not learn the cost until pickup has no opportunity to discuss alternatives with their prescriber, and the pharmacy has already invested labor and materials in a preparation that may go uncollected.

Structuring the compounding pharmacy intake for clinical excellence

The thread connecting every section of a compounding pharmacy intake form is the same: the pharmacist is manufacturing a medication, not dispensing one. Every manufacturing decision, from the choice of base to the selection of preservative system to the concentration calculation to the beyond-use date assignment, depends on patient-specific information that the intake form either provides or fails to provide. A compounding pharmacy that uses a generic retail pharmacy intake form is making manufacturing decisions without the information those decisions require. That is not a documentation gap. It is a clinical risk.

The intake form is also the compounding pharmacy's most important regulatory compliance document. State board auditors, FDA inspectors examining 503A compliance, and attorneys reviewing adverse event claims will all look first at what the pharmacy knew about the patient at the time of compounding. An intake form that captured the patient's complete allergy profile, documented the clinical reason for compounding versus commercial dispensing, and recorded the patient's formulation preferences demonstrates a standard of care that protects the pharmacy. An intake form that captured nothing beyond demographics and insurance demonstrates that the pharmacy was compounding blind.

A compounding pharmacy that invests in its intake process invests in every preparation it makes. The allergy profile prevents adverse reactions. The medication history prevents duplications and interactions. The formulation preference documentation prevents waste and non-adherence. The prescriber communication infrastructure enables the ongoing clinical dialogue that titrated therapy requires. The compliance documentation satisfies the regulatory scrutiny that compounding inevitably attracts. The financial transparency prevents the billing surprises that drive patients away. None of this is possible with a name, a date of birth, and a checkbox.

If your pharmacy is evaluating its intake process alongside broader clinical documentation, the Healthcare Bundle provides 21 profession-specific form sets designed for clinical environments, including pharmacy intake documentation that captures the depth of information compounding requires.

Streamline Your Compounding Pharmacy Intake Process

Fillable PDF intake form + client questionnaire designed for compounding pharmacies. Captures allergy profiling, medication history with commercial formulation failures, dosage form preferences, HRT protocol documentation, veterinary compounding, prescriber communication, insurance and payment, and regulatory compliance fields. Ready to use, ready to customize.

View Pharmacy Forms Healthcare Bundle